Spero Therapeutics, Inc.
SPRO· Nasdaq
Released Nov 10, 2021, after the close
10-Q filed Nov 10, 2021, 41 days after period end · 0000950170-21-004064
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $708.00K | $38.00K | $172.00K | $658.00K |
| Net Income | -$22.50M | -$18.90M | -$17.70M | -$10.46M |
| EPS Diluted |
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR
| -$0.70 |
| -$0.86 |
| -$0.95 |
| -$0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.